<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474562</url>
  </required_header>
  <id_info>
    <org_study_id>YMC032</org_study_id>
    <nct_id>NCT03474562</nct_id>
  </id_info>
  <brief_title>High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension</brief_title>
  <official_title>Effect of High-Dose Rosuvastatin Combined With Telmisartan or Amlodipine on Glucose Metabolism in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Impaired Fasting Glucose (IFG) and Hypertension: A Randomized, Open-Label, Parallel, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of high-dose rosuvastatin combined with telmisartan or&#xD;
      amlodipine on glucose metabolism in ASCVD patients with impaired fasting glucose and&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 24 in homeostasis model assessment for insulin resistance (HOMA-IR)</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in HOMA-IR</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in insulin level</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in homeostatic model assessment for β-cell function (HOMA-B)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in C-reactive protein (CRP)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>ASCVD</condition>
  <condition>Impaired Fasting Glucose</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Duowell Tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40mg/Rosuvastatin 20mg qd for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monorova Tab + Amlopin Tab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20mg + Amlodipine 5mg qd for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duowell®</intervention_name>
    <description>Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP &gt; 140mmHg or DBP &gt; 90mmHg at week 12)</description>
    <arm_group_label>Duowell Tab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monorova® + Amlopin®</intervention_name>
    <description>Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP &gt; 140mmHg or DBP &gt; 90mmHg at week 12)</description>
    <arm_group_label>Monorova Tab + Amlopin Tab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Aged 19 to 75 years&#xD;
&#xD;
          3. Patients with ASCVD requiring high-intensity statin therapy (in accordance with the&#xD;
             clinical ASCVD diagnostic criteria in the 2013 ACC/AHA Guideline)&#xD;
&#xD;
             - Coronary artery disease&#xD;
&#xD;
               -  acute coronary syndrome&#xD;
&#xD;
               -  history of myocardial infarction (MI)&#xD;
&#xD;
               -  stable or unstable angina&#xD;
&#xD;
               -  history of coronary revascularization&#xD;
&#xD;
               -  stroke or transient ischemic attack (TIA)&#xD;
&#xD;
               -  peripheral arterial disease, history of peripheral arterial revascularization&#xD;
&#xD;
          4. Those who are taking antihypertensive drugs, or SBP &gt; 140mmHg or DBP &gt; 90mmHg on the&#xD;
             left side&#xD;
&#xD;
          5. High-risk group (except for gestational diabetes) who has not been diagnosed with&#xD;
             diabetes before, and who falls under one of the following criteria:&#xD;
&#xD;
               -  impaired fasting glucose (IFG): 100-125 mg/dL (5.6-6.9 mmol/L)&#xD;
&#xD;
               -  impaired glucose tolerance (IGT): plasma blood glucose 140-199mg/dL (7.8 to 11.0&#xD;
                  mmol/L) 2 hours after oral administration of glucose 75g&#xD;
&#xD;
               -  HbA1c: 5.7-6.4%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who are treated with secondary hypertension or malignant hypertension&#xD;
&#xD;
          2. Uncontrollable diabetes with HbA1c ≥ 10%&#xD;
&#xD;
          3. Total cholesterol ≥ 300mg/dL&#xD;
&#xD;
          4. Fasting LDL-C ≤ 70 mg/dL&#xD;
&#xD;
          5. Fasting triglyceride ≥ 500 mg/dL&#xD;
&#xD;
          6. History of muscular disease or rhabdomyolysis due to use of statin&#xD;
&#xD;
          7. Hypersensitive to statin or ARBs&#xD;
&#xD;
          8. Contraindications stated in the SPC of telmisartan or rosuvastatin including the&#xD;
             following:&#xD;
&#xD;
               -  severe renal disease (CrCL &lt; 30mL/min: Cockcroft-gault formula or estimated GFR&#xD;
                  (MDRD) &lt; 30mL/min/1.73m2)&#xD;
&#xD;
               -  ALT, AST &gt; 3x ULN or history of active liver disease&#xD;
&#xD;
               -  CPK &gt; 3x ULN&#xD;
&#xD;
               -  hyperkalemia with serum K &gt; 5.5 mEq/l&#xD;
&#xD;
          9. Those who are participating in clinical trials of other investigational products&#xD;
&#xD;
         10. Those who cannot discontinue all other treatment for hypertension or hyperlipidemia&#xD;
             than the investigational products, and concomitant medications and supplements that&#xD;
             can affect the therapeutic effect of hypertension and hyperlipidemia during the trial&#xD;
             period&#xD;
&#xD;
         11. Other than the above who is deemed to be ineligible to participate in the trial by&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

